These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 15589593)

  • 1. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma.
    Tate S; Hirai Y; Takeshima N; Hasumi K
    Gynecol Oncol; 2005 Jan; 96(1):143-9. PubMed ID: 15589593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic value of serum CA(125) level change during chemotherapy post-surgery in patients with advanced epithelial ovarian carcinoma].
    Lan CY; Huang H; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):732-6. PubMed ID: 19087537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
    van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
    Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relationship between CA125 half life during neoadjuvant chemotherapy and the optimal operation rate and prognosis in patients with advanced epithelial ovarian carcinoma].
    Xi XW; Wan XP; Li SD; Sun TW; Zhu YP
    Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):91-4. PubMed ID: 16640855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Le T; Hopkins L; Faught W; Fung-Kee-Fung M
    Gynecol Oncol; 2007 Jun; 105(3):712-5. PubMed ID: 17400284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
    Yang R; Feng J; Fang XZ; Bai F; Cheng YX; Liu C; Zhu W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):459-63. PubMed ID: 17083811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
    Kang WD; Choi HS; Kim SM
    Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
    Markman M; Federico M; Liu PY; Hannigan E; Alberts D
    Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
    Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
    Gadducci A; Zola P; Landoni F; Maggino T; Sartori E; Bergamino T; Cristofani R
    Gynecol Oncol; 1995 Jul; 58(1):42-7. PubMed ID: 7789889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognosis and prognostic factor analysis epithelial ovarian cancer].
    Wen H; Sun W; Guo Y
    Zhonghua Fu Chan Ke Za Zhi; 1997 Mar; 32(3):159-62. PubMed ID: 9596891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
    Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
    Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
    Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
    Bădulescu F; Bădulescu A; Schenker M; Popescu CF; Stoica Z
    Rom J Morphol Embryol; 2005; 46(4):329-34. PubMed ID: 16688372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.